Floatz logo

Lorcaserin

Schizoaffective Disorder

University of North Carolina, Chapel HillSmall moleculePhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Schizoaffective Disorder cohort.

Asset / SponsorPhaseRating
Paliperidone
Luye Pharma Group Ltd.
Phase 4BBB
Lurasidone
University of Texas Southwestern Medical Center
Phase 4BBB
Risperidone
Lyndra Inc.
Phase 4BBB
Quetiapine
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 4BBB
Olanzapine
The Royal Ottawa Mental Health Centre
Phase 4BBB

View all 50 →

Same molecule, other indications

Lorcaserin is also rated in:

obesity disorderActive
BB
Indicative · Phase 4
66 / 100
View asset →
cardiovascular disorderDormant
B
Indicative · Phase 4
63 / 100
View asset →
nicotine dependenceDormant
B
Indicative · Phase 2/3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →